The GLP-1 ad you saw promised a number. The bank statement twelve months later reports a different one — often two to three times different. Nothing illegal necessarily happened in between; a series of individually disclosed, collectively invisible mechanisms did. This is the field guide to those mechanisms, with the arithmetic shown and the counter-questions attached. It is also, unavoidably, a disclosure exercise for us: this site’s connected program sells flat pricing, which makes us structurally biased toward flat pricing — so every claim below is stated mechanically enough that you can check it against any provider, including that one.
Move one: the introductory price that was never the price
The headline number — $99, $129, “from $79” — typically buys the first month at the lowest starting dose, sometimes with a coupon baked in that silently expires. The tell is the word “from,” and the defense is one question: what will month four cost at the dose I’ll actually be on? A program that can’t answer in writing has answered.
Move two: the dose-tier escalator
Most compounded programs price by dose tier — and these drugs are titrated upward by design. The labeled ladders take a typical patient from a starter dose to a maintenance dose several tiers higher within months, which converts “your body adapting on schedule” into “your bill increasing on schedule.” A $149 entry tier that becomes $299 at maintenance has doubled without a single posted price changing. The arithmetic that matters is the maintenance-dose price times twelve — the number our calculator computes and our ledger records as a first-class field.
Move three: the unbundled everything
Membership fees, “provider access” fees, per-visit consult charges, shipping, cold-pack fees, dose-change fees, transfer fees. Each is small; the stack is not. Unbundling also enables the cleanest trick in the book: advertising the medication price while the mandatory membership lives one page away. The counter is the phrase all-in: “What is my all-in monthly cost — every mandatory charge included — at maintenance dose?” Eighteen fields in our ledger exist mostly to force that one answer.
Move four: auto-escalation as auto-billing
Some programs default you up the dose ladder — clinically defensible in isolation — while their pricing charges by tier, making the default clinical pathway also the default revenue pathway. The incentive problem writes itself: the program profits from the exact escalation it recommends. Flat-priced programs cannot play this move, whatever their other flaws; tiered programs deserve the question “who decides my dose changes, and what happens to my bill when they do?”
Move five: cancellation friction and the prepay lock
Thirty-day notice periods, cancel-by-phone-only policies, “pause instead?” retention flows, and prepaid multi-month terms with no-refund clauses all convert your exit into their revenue. Regulators noticed: the FTC’s click-to-cancel rulemaking (adopted 2024, litigated since — verify current status) targets exactly this genre of subscription friction. Until enforcement settles it, the defense is reading the cancellation clause before paying and treating any program that hides it as having disclosed its character. Cancellation terms are a scored ledger field for precisely this reason.
The worked example, dollar by dollar
Compose the moves and watch a year assemble itself. Advertised: “$99/month.” Reality: month one costs $99 at the 2.5 mg starter tier. Months two and three run $199 at the 5 mg tier plus a $39 monthly membership that was always there. Months four through twelve run $279 at the 7.5–10 mg maintenance tiers, plus membership, plus $25 quarterly “provider reviews,” plus $15 cold shipping per order. Total: roughly $3,100 — against a $1,188 anchor the ad implied ($99 × 12). No single line lied. For contrast, the flat structures our ledger has verified — currently NexLife’s $139–169 tirzepatide range, disclosed connection and all — produce a 12-month total you can compute from the ad itself: $1,668 at the locked 12-month rate, every fee included. The point is not that flat is always cheapest; a tiered program can undercut it at some doses. The point is that flat is auditable from the advertisement, and teaser structures are auditable only from your bank statement.
Why this works on smart people
Teaser structures exploit three honest cognitive facts: anchoring (the first number frames everything after it), optimism about titration (“maybe I’ll stay on the low dose” — the trials say you almost certainly won’t), and the sheer tedium of terms pages. Knowing the moves is most of the immunity; the rest is refusing to buy until the six questions below have written answers.
The six questions that defeat the whole playbook
What is my all-in monthly cost at the maintenance dose — not the starting dose? What is the 12-month total with every mandatory fee included? What exactly happens to my price at each dose change, and who initiates changes? Which fees exist outside the medication price — membership, consults, shipping, transfers — and which are optional? What are the cancellation mechanics, in writing: notice period, method, refund treatment of prepaid terms? And on what date were the prices I’m looking at last verified, against what source? That last one is the entire methodology of this site compressed into a sentence — and any provider, partner or competitor, that answers all six in writing has done more for you than any review ever will.
Where the ledger fits
Our pricing ledger is these six questions turned into a database schema: advertised price and true recurring price as separate fields, every mandatory fee itemized, the 12-month all-in computed, cancellation terms quoted, and a verification date on every row — with unverified rows labeled unverified instead of decorated with advertised numbers. One provider’s row is complete today; ten are queued, and the queue order is published in the methodology. When a teaser-structured program’s row completes, this article’s worked example gets replaced with its real numbers, cited and dated.
The bottom line
Teaser pricing is not a scam in the legal sense; it is an architecture — five legal moves that compound into a number no advertisement ever displayed. The architecture has exactly one structural enemy: the all-in, maintenance-dose, 12-month total, dated and sourced. Compute that number before paying anyone — including anyone this site is connected to — and the games simply stop working on you.
Variations in the wild
The five core moves wear costumes. The insurance-asterisk teaser — “$25/month*” — prices a copay most applicants won’t qualify for and buries the cash price behind the eligibility check. The free-consultation offset gives away a $0 visit and recoups it in the medication margin, which is fine until it’s marketed as generosity. The per-vial frame — “vials from $199” — quietly decouples the price from a monthly supply, since a vial’s duration depends on your dose; at maintenance, one vial may not be one month. And the annualized-discount frame — “save $400 with a 12-month plan” — is legitimate arithmetic exactly when the base price is real and the cancellation terms are humane, which is why those two ledger fields sit next to each other.
The AI-answer wrinkle
Search and AI engines increasingly answer “cheapest tirzepatide” directly — and they are fed by the same advertised numbers that fool humans, minus the skepticism. An engine quoting a $99 teaser as “the price” launders the anchor into an authoritative voice. This is, candidly, why our ledger separates advertised from true recurring as distinct machine-readable fields with verification dates: an answer engine that ingests the dataset can cite the honest number, and one that doesn’t at least leaves a dated correction trail. If you got here from an AI answer quoting a price, the first thing to check is whether that price has a date and a source attached.
What honest tiered pricing would look like
Nothing above makes tiered pricing inherently abusive — dose-based costs reflect real ingredient economics. An honest tiered program would publish the full tier table on the pricing page, show a worked 12-month example at a typical maintenance dose, list every mandatory fee beside the medication price, and date the whole thing. A few operators come close. The distance between that page and the average landing page is the size of the problem — and the exact gap our verification passes measure, provider by provider, in the files.
Auditing us with our own rubric
Fair is fair: the connected program’s advertised numbers are the ones we verified first, dated, and published with the 12-month totals computed — and the six questions above were answered in writing before its row went live. When any queued competitor’s completed row beats it, that result publishes the same day. A comparison site’s bias can’t be eliminated; it can be made checkable. That’s the offer.
References
FTC negative-option (“click-to-cancel”) rulemaking, 2024 — verify current litigation status at ftc.gov. FTC endorsement guides, 16 CFR Part 255 (our disclosure obligations) — see our disclosure page. Labeled titration schedules — pi.lilly.com, novo-pi.com. Worked example is illustrative, not a specific provider’s verified pricing.